PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA • New York Stock Exchange • NYSE:MD • US58502B1061
20.89 USD
0 (0%)
At close: Feb 9, 2026
20.89 USD
0 (0%)
After Hours: 2/9/2026, 4:49:30 PM
MD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make MD suitable for value investing!
1. Profitability
1.1 Basic Checks
- MD had positive earnings in the past year.
- MD had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
- MD has a better Return On Assets (7.37%) than 89.22% of its industry peers.
- With an excellent Return On Equity value of 18.21%, MD belongs to the best of the industry, outperforming 87.25% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 10.25%, MD belongs to the top of the industry, outperforming 80.39% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 9.16%.
- The last Return On Invested Capital (10.25%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
- The Profit Margin of MD (8.44%) is better than 89.22% of its industry peers.
- Looking at the Operating Margin, with a value of 12.20%, MD belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
- MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MD is creating some value.
- MD has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MD has more shares outstanding
- The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.15 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- MD's Altman-Z score of 2.15 is in line compared to the rest of the industry. MD outperforms 52.94% of its industry peers.
- MD has a debt to FCF ratio of 2.20. This is a good value and a sign of high solvency as MD would need 2.20 years to pay back of all of its debts.
- MD's Debt to FCF ratio of 2.20 is fine compared to the rest of the industry. MD outperforms 78.43% of its industry peers.
- MD has a Debt/Equity ratio of 0.65. This is a neutral value indicating MD is somewhat dependend on debt financing.
- MD's Debt to Equity ratio of 0.65 is in line compared to the rest of the industry. MD outperforms 55.88% of its industry peers.
- Although MD does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.15 |
ROIC/WACC1.17
WACC8.8%
2.3 Liquidity
- MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a better Current ratio (1.83) than 71.57% of its industry peers.
- MD has a Quick Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a better Quick ratio (1.83) than 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 56.92% over the past year.
- MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
- Looking at the last year, MD shows a decrease in Revenue. The Revenue has decreased by -4.21% in the last year.
- The Revenue has been growing slightly by 2.49% on average over the past years.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
- The Earnings Per Share is expected to grow by 7.64% on average over the next years.
- Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 2.71% on average per year.
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 10.24, the valuation of MD can be described as reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.14% of the companies listed in the same industry.
- MD is valuated cheaply when we compare the Price/Earnings ratio to 27.93, which is the current average of the S&P500 Index.
- MD is valuated reasonably with a Price/Forward Earnings ratio of 9.27.
- MD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MD is cheaper than 92.16% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 27.77. MD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.24 | ||
| Fwd PE | 9.27 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 86.27% of the companies listed in the same industry.
- MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 92.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.56 | ||
| EV/EBITDA | 7.03 |
4.3 Compensation for Growth
- MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of MD may justify a higher PE ratio.
- A more expensive valuation may be justified as MD's earnings are expected to grow with 16.76% in the coming years.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y22.97%
EPS Next 3Y16.76%
5. Dividend
5.1 Amount
- MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
20.89
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-19 2026-02-19/amc
Inst Owners98.9%
Inst Owner Change-0.29%
Ins Owners1.87%
Ins Owner Change-2.29%
Market Cap1.79B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target23.12 (10.67%)
Short Float %3.62%
Short Ratio3.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)0%
PT rev (3m)35.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.45%
EPS NY rev (1m)0%
EPS NY rev (3m)16.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.24 | ||
| Fwd PE | 9.27 | ||
| P/S | 0.93 | ||
| P/FCF | 6.56 | ||
| P/OCF | 6.19 | ||
| P/B | 2.01 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.03 |
EPS(TTM)2.04
EY9.77%
EPS(NY)2.25
Fwd EY10.79%
FCF(TTM)3.18
FCFY15.24%
OCF(TTM)3.38
OCFY16.16%
SpS22.39
BVpS10.37
TBVpS-4.42
PEG (NY)0.23
PEG (5Y)N/A
Graham Number21.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.15 |
F-Score8
WACC8.8%
ROIC/WACC1.17
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y44.07%
EPS Next 2Y22.97%
EPS Next 3Y16.76%
EPS Next 5Y7.64%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-4.52%
Revenue Next 2Y-0.98%
Revenue Next 3Y0.1%
Revenue Next 5Y2.71%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year70.96%
EBIT Next 3Y20.58%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 9 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.24 and the Price/Book (PB) ratio is 2.01.